Company news

Actinogen Medical Limited news in 2016

Actinogen Medical Limited's news releases, calls and decks from 2016, newest first.

View company

Significant Advance in Development of Alzheimers Drug

December 18, 2016

FDA Feedback on Xanamem Alzheimers Trail

September 29, 2016

R&D Tax Rebate

September 4, 2016

New Patents Allowed for B-HSD1 Inhibitor

August 2, 2016

Further results in bio-ethanol test program

August 2, 2016

Announcement of non-renounceable rights issue

August 2, 2016

Appendix 4C & Commentary

August 2, 2016

Landmark Research on Excess Cortisol & Alzheimers Disease

July 27, 2016

US Patent Granted-Further Extends Xanamem Protection

July 19, 2016

US FDA Feedback Enhances Alzheimers Study

June 7, 2016

Launch of XanADu Phase II Clinical Trial

March 21, 2016

Appendix 4D & Half Year Report

February 19, 2016

R&D Rebate

February 11, 2016

Update on the Biofuel Research Program

February 10, 2016

Trials recommence on antibiotic project

February 10, 2016

Suspension of ACWN and ACWO 1/08/13

February 10, 2016

Supplementary prospectus - withdrawal of offer

February 10, 2016

Supplementary prospectus and amended timetable

February 10, 2016

Successful Completion of 1st Stage of Alzheimers Drug Trial

February 10, 2016

Successful Capital Raising to Support Alzheimers Research

February 10, 2016

Shareholder Update

February 10, 2016

Rights issue prospectus (with amended timetable)

February 10, 2016

Rights Issue Prospectus

February 10, 2016

Rights issue closure and notice of remaining shortfall

February 10, 2016

Response to Price Query Letter

February 10, 2016

Response to ASX query

February 10, 2016

Response to ASX Appendix 4C Query

February 10, 2016

Response to ASX Appendix 4C query

February 10, 2016

Response to Appendix 4C ASX Query

February 10, 2016

Resonse to ASX Query - Price Query

February 10, 2016

Range of Patented Biodegradable Nappies etc to be developed

February 10, 2016

R&D Tax Rebate Received

February 10, 2016

Preliminary Final Report - Appendix 4E

February 10, 2016

Preliminary Final Report

February 10, 2016

Positive Trial Results for Alzheimers Drug Xanamem

February 10, 2016

Placement, Appendix 3B & Section 708A Notice

February 10, 2016

Non-Renounceable Rights Issue and Prospectus

February 10, 2016

New patent application for biofumigation process

February 10, 2016

New Discovery of Making Shikimic Acid

February 10, 2016

New Discovery for Plant Growth in Wheat, Peas and Broad Bean

February 10, 2016

New Biodegradable Shopping Bags and many other products

February 10, 2016

Market Update and Clarification

February 10, 2016

Independent trials being conducted on Plant Growth Hormones

February 10, 2016

Further Clinical Trial Update on Xanamem

February 10, 2016

First Participants Recruited for 2nd Phase 1 Xanamem Study

February 10, 2016

Excellent Research Progress with Promising Alzheimers Drug

February 10, 2016

EU Patent Granted-Further Extends Xanamem Protection

February 10, 2016

Ethics Approval Granted for Second Phase 1 Study of Xanamem

February 10, 2016

Ethics Approval Granted for 2nd Stage of Phase 1 Study

February 10, 2016

Discovery of New Method to produce Anacardic Acid

February 10, 2016

Older news releases →

Decks in 2016